Marginum aims to improve the outcome and cost-effectiveness of cancer
surgery with novel fluorescence-based optical tissue monitoring technology.
The company completed its €1.7 million seed funding round by raising private capital
from Almaral, Nostetta Ventures, Redstone coupled with Business Finland loan.
Marginum’s solution empowers surgeons with fast and reliable information about
tumour tissues. Accurate identification of tumours and distinguishing them from
healthy tissues during cancer surgery is a critical challenge faced by surgeons
globally. With an ageing population and the projected 55 % increase in global
cancer incidence by 2040, there will be over 20 million cancer patients each year in
need of surgery.
The company is dedicated to improving patient safety and surgical performance
without compromising the pre-existent workflow. The technology enables surgeons
to verify whether or not a resected area included tumour in near real-time. This is
expected to translate to more informed and targeted resections; therefore
decreasing reoperations and adverse effects.
“Almaral invests in early-stage biotech and life science companies with
technologies that can significantly enhance healthcare professionals&#39; ability to
deliver services with improved efficiency, quality, or significantly reduced costs,
without compromising the quality of care. Marginum enables fundamental changes
in the surgical market and contributes to solving a global health issue”, states Dr.
Maria Severina, CEO of Almaral.